The Spring 2026 issue previews SATA’s annual symposium at the Fairmont Queen Elizabeth in Montreal (May 3–4, 2026) and welcomes Dr. Lorenzo De Marchi as the new SATA President. Inside: UNOS news on CMS reforms, the FY26 federal funding package, and UNOS’s response to recent Bloomberg allegations; research on back-to-base machine perfusion, ILTS-iLDLT 2025 living donor safety guidelines, and HCC recurrence with intraoperative blood salvage; a feature on ICU liberation after liver transplant and where ERAS stands today; and a program spotlight on the University of Pennsylvania, including their pioneering work in extracorporeal liver cross-circulation with genetically modified pig livers.
Inside This Issue
- Upcoming Events — The 2026 SATA Symposium at the Fairmont Queen Elizabeth Hotel in Montreal (May 3–4, 2026); complimentary registration for new 2026 members
- UNOS News — UNOS supports the CMS proposed rule on electronic donor referrals and organ tracking, the FY26 Federal Funding Package directs HHS/HRSA to implement automated donor referrals and real-time organ tracking, and UNOS responds to Bloomberg Government’s Grassley/Wyden allegations
- Research Corner — Back-to-base vs. in-transit DCD liver machine perfusion (Alderete et al.), ILTS-iLDLT 2025 living liver donor safety guidelines (Bhangui et al.), HCC recurrence with intraoperative blood salvage (Butler et al.), and a case report of a 14,200cc polycystic liver transplant (Salazar et al.)
- ICU Liberation After Liver Transplant — Drs. Tony Wang and Sergio Navarrete on the ERAS4OLT.org/ILTS consensus framework, strong evidence for early extubation (Tinguely meta-analysis), broader ERAS outcomes, and patient selection criteria for fast-tracking
- SATA Member Corner — Dr. Lorenzo De Marchi (Georgetown), current SATA President and Director of Liver Transplant Anesthesia, on his journey from Milan to Georgetown, the founding of SATA’s TEE working group, and his research on methylated cell-free DNA as a liver injury biomarker
